Based on the Vertex Pharmaceuticals Inc stock forecast from 23 analysts, the average analyst target price for Vertex Pharmaceuticals Inc is USD 493.17 over the next 12 months. Vertex Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Vertex Pharmaceuticals Inc is Bullish , which is based on 10 positive signals and 4 negative signals. At the last closing, Vertex Pharmaceuticals Inc’s stock price was USD 397.27. Vertex Pharmaceuticals Inc’s stock price has changed by -14.33% over the past week, -11.96% over the past month and -0.74% over the last year.
No recent analyst target price found for Vertex Pharmaceuticals Inc
No recent average analyst rating found for Vertex Pharmaceuticals Inc
Company Overview Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Read Less
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for ...Read More
Frequently Asked Questions About Vertex Pharmaceuticals Inc (VRTX) Stock
Based on ratings from 23 analysts Vertex Pharmaceuticals Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bullish . The stock has 24 buy, 1 sell and 16 hold ratings.
Unfortunately we do not have enough data on VRTX's stock to indicate if its a good dividend stock.
Based on targets from 23 analysts, the average taret price for VRTX is USD 493.17 over the next 12 months. The maximum analyst target price is USD 600 while the minimum anlayst target price is USD 297.
VRTX stock's Price/Earning ratio is 32.57.
Our analysis grades VRTX stock's Price / Earning ratio at F. This means that VRTX stock's Price/Earning ratio is above 79% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this VRTX may be a overvalued for its sector.
The last closing price of VRTX's stock was USD 397.27.
The most recent market capitalization for VRTX is USD 120.60B.
Based on targets from 23 analysts, the average taret price for VRTX is projected at USD 493.17 over the next 12 months.
This means that VRTX's stock price may go up by +24.14% over the next 12 months.
We can't find any ETFs which contains Vertex Pharmaceuticals Inc's stock.
As per our most recent records Vertex Pharmaceuticals Inc has 5,400 Employees.
Vertex Pharmaceuticals Inc's registered address is 50 Northern Avenue, Boston, MA, United States, 02210.
You can get more information about it from Vertex Pharmaceuticals Inc's website at https://www.vrtx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Vertex Pharmaceuticals Inc (VRTX) Stock
Based on ratings from 23 analysts Vertex Pharmaceuticals Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bullish . The stock has 24 buy, 1 sell and 16 hold ratings.
Unfortunately we do not have enough data on VRTX's stock to indicate if its a good dividend stock.
Based on targets from 23 analysts, the average taret price for VRTX is USD 493.17 over the next 12 months. The maximum analyst target price is USD 600 while the minimum anlayst target price is USD 297.
VRTX stock's Price/Earning ratio is 32.57.
Our analysis grades VRTX stock's Price / Earning ratio at F. This means that VRTX stock's Price/Earning ratio is above 79% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this VRTX may be a overvalued for its sector.
The last closing price of VRTX's stock was USD 397.27.
The most recent market capitalization for VRTX is USD 120.60B.
Based on targets from 23 analysts, the average taret price for VRTX is projected at USD 493.17 over the next 12 months.
This means that VRTX's stock price may go up by +24.14% over the next 12 months.
We can't find any ETFs which contains Vertex Pharmaceuticals Inc's stock.
As per our most recent records Vertex Pharmaceuticals Inc has 5,400 Employees.
Vertex Pharmaceuticals Inc's registered address is 50 Northern Avenue, Boston, MA, United States, 02210.
You can get more information about it from Vertex Pharmaceuticals Inc's website at https://www.vrtx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for VRTX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
